Stopped at the Threshold: The Practical Impact of the Supreme Court’s Mayo and Myriad Decisions on Biotechnology Patent Practices

The Supreme Court’s recent decisions in Mayo Collaborative Services v. Prometheus Labs and Association for Molecular Pathology v. Myriad Genetics have drastically changed the outlook for applicants seeking biotechnology patents. Get an overview of the changes and what they mean for the biotechnology industry with the our study, Stopped at the Threshold: The Practical Impact of the Supreme Court's Mayo and Myriad Decisions on Biotechnology Patent Practices.

 

Written in conjunction with BIO and law firm Robins, Kaplan, Miller & Ciresi L.L.P, the study includes:

 

  • The results of a survey of 1,500 patents applications to determine how the PTO has examined claims under Section 101 since the Supreme Court decided Mayo and Myriad.
  • Detailed explanations of the key impacts of the decisions on biotechnology patents and how the PTO's new patent guidance may impact the public’s access to new medicines and diagnostics.
  • Comments from patent attorneys on their real-world experiences with examiners in the wake of these decisions and the impact of the PTO's guidance.

 

REGISTER NOW